Abstract Number: 1525 • 2018 ACR/ARHP Annual Meeting
Effect of JAK-Inhibitor Versus Bdmards on Quality of Life in Rheumatoid Arthritis : A Meta Analysis of Randomized Controlled Trials
Background/Purpose: Recent studies comparing JAK-inhibitors (Jak-i) and adalimumab seem to show a better efficacy of JAK-i on patient-reported outcomes in rheumatoid arthritis (RA). As there…Abstract Number: 1526 • 2018 ACR/ARHP Annual Meeting
Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The purpose of this study is to describe the profile of patients…Abstract Number: 1527 • 2018 ACR/ARHP Annual Meeting
Tofacitinib Improves Left Ventricular Mass and Cardiac Output in Rheumatoid Arthritis Patients with Chronic Heart Failure
Background/Purpose: Rheumatologists need to develop primary and secondary prevention strategies for cardiovascular disease (CVD) in rheumatoid arthritis (RA) patients. We reported tofacitinib (Tofa) (with or…Abstract Number: 1528 • 2018 ACR/ARHP Annual Meeting
Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)
Background/Purpose: Anemia (WHO criteria: Hemoglobin [Hb] levels <12.0 g/dL [females] or <13.0 g/dL [males]) is a common finding associated with increased joint inflammation in patients…Abstract Number: 1529 • 2018 ACR/ARHP Annual Meeting
Long-Term, Real-World Safety of Adalimumab in Rheumatoid Arthritis
Background/Purpose: The incidence of adverse events (AE) among rheumatology medication users has not been well documented in real-world disease registry datasets in the US. We…Abstract Number: 1530 • 2018 ACR/ARHP Annual Meeting
CRP Changes during Bacterial Infections in Baricitinib-Treated Patients with RA
Background/Purpose: Baricitinib (BARI) is a selective inhibitor of Janus kinase 1/2, modulating responses to inflammatory cytokines, e.g. IL-6 or IFNs1. During acute inflammation, including those…Abstract Number: 1531 • 2018 ACR/ARHP Annual Meeting
Tofacitinib Show Similar Retention When Used with and without Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry
Background/Purpose: Tofacitinib (TOFA), a targeted synthetic DMARD has recently appeared on the Canadian market. It is an oral agent, targeting the JAK 1 and JAK…Abstract Number: 1532 • 2018 ACR/ARHP Annual Meeting
Impact of Immunogenicity on Clinical Efficacy and Administration Related Reaction in TNF Inhibitors: A Pooled-Analysis from Three Biosimilar Studies in Patients with Rheumatoid Arthritis
Background/Purpose: SB4, SB2, and SB5 are biosimilars of reference etanercept, infliximab, and adalimumab, respectively. The phase III randomized, double-blind clinical studies comparing the efficacy and…Abstract Number: 1533 • 2018 ACR/ARHP Annual Meeting
Simulating Population Disability Outcomes for Alternative Treatment Pathways in Patients with Active Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that causes joint pain and swelling, bone erosions, and deformity. This debilitating disease can severely…Abstract Number: 1534 • 2018 ACR/ARHP Annual Meeting
Comparative Risk of Diabetes Mellitus in Rheumatoid Arthritis Patients Treated with Different Biologics- a Cohort Study
Background/Purpose: Patients with rheumatoid arthritis (RA) often develop diabetes mellitus (DM), potentially due to aggravated systemic inflammation. Reducing inflammation with disease-modifying antirheumatic drugs (DMARD) may…Abstract Number: 1535 • 2018 ACR/ARHP Annual Meeting
Enhancing Patient Ability to Process and Use Information about Medication Risks and Benefits
Background/Purpose: Guidelines for the treatment of rheumatoid arthritis (RA) underscore the importance of an early and targeted approach to control inflammation. However, patients are often…Abstract Number: 1536 • 2018 ACR/ARHP Annual Meeting
Mean Platelet Volume Changes with Baricitinib Indicate Reduced New Platelet Production in Baricitinib-Treated Rheumatoid Arthritis Patients
Background/Purpose: Transient increases in circulating platelets were observed in patients with RA treated with baricitinib, an oral selective Janus kinase 1/2 inhibitor, approved for the…Abstract Number: 1537 • 2018 ACR/ARHP Annual Meeting
Frequency and Duration of Early Non-Serious Adverse Events in Rheumatoid Arthritis Patients Treated with Tofacitinib 5 Mg Twice Daily As Monotherapy and Combination Therapy
Background/Purpose: Tolerability remains ill-defined in clinical trials and most commonly refers to non-serious adverse events (AEs) that may impact patient (pt) satisfaction and adherence to…Abstract Number: 1538 • 2018 ACR/ARHP Annual Meeting
Moderate Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
Background/Purpose: In rheumatology, we are aware of the possibility to develop adverse drug reactions (ADR) to the widely used Disease Modifying Drugs (DMARD). We are…Abstract Number: 1539 • 2018 ACR/ARHP Annual Meeting
Safety of Methotrexate and Leflunomide Combination Therapy in the Treatment of Rheumatoid Arthritis
Background/Purpose: Best treatment of Rheumatoid Arthritis (RA) requires to begin early, with a tight control, including nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, disease-modifying antirheumatic drugs (DMARDs)…
ACR Meeting Abstracts